Identification of fully ‘human monoclonal antibodies’ against the intractable disease targets will be the main objective of a new research collaboration between ”Genmab” and “Pepscan Therapeutics”, the companies from Denmark and Netherland respectively.
Present technological set up has its own limitations with such identification and it has become more urgent to device new techniques to address the issue. It could be mainly due to the fact that the target proteins are deposited in a large quantity near the cell surface or within the cell membrane. There may be other reasons as well like the poor immunogenicity of the protein or the epitopes that are required.
Both the companies feel that the collaboration would facilitate detailed evaluation of the disease targets and it will help in addressing and evolving new standard treatments.
Monoclonal Antibodies against intractable targets are a significant unmet need. A combination of ‘Pepscan CLIPS protein mimicry platform’ and the ‘Genmab’s ability to generate fully ‘human monoclonal’ will enable the partners to develop innovative products for poorly served indications.
continue reading Human Monoclonal Antibodies Could Be Beneficial to Address Intractable Diseases
